Pfizer’s Lavish Leap: An Earnings Waltz in a Gilded Ballroom

The second quarter’s curtain rose on a tableau vividly painted in dollar signs: adjusted diluted earnings per share of $0.78, with nearly $14.7 billion in revenue. These were numbers positively baroque in their excess, outpacing consensus estimates as if consensus had arrived embarrassingly underdressed. FactSet, bless them, was caught $0.20 and over $1 billion out. Such charming imprecision.








